Anika Therapeutics (ANIK) Retained Earnings (2010 - 2026)

Anika Therapeutics (ANIK) has reported Retained Earnings for 17 consecutive years, with $59.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings fell 6.02% year-over-year to $59.0 million in Q2 2026; TTM through Jun 2026 was $59.0 million, a 6.02% decrease from a year earlier, with the FY2025 full-year figure at $60.8 million, down 15.18% from the prior year.
• Retained Earnings was $59.0 million for Q2 2026 at Anika Therapeutics, up from $55.7 million in the prior quarter.
• Over five years, Retained Earnings peaked at $222.6 million in Q1 2022 and troughed at $55.7 million in Q1 2026.
• A 5-year average of $131.3 million and a median of $123.5 million in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings fell 0.73% in 2022 and slumped 51.04% in 2024, its largest moves.
• Over 5 years, Retained Earnings stood at $210.7 million in 2022, then slumped by 39.23% to $128.1 million in 2023, then slumped by 44.03% to $71.7 million in 2024, then decreased by 15.18% to $60.8 million in 2025, then dropped by 2.87% to $59.0 million in 2026.
• The last three Retained Earnings figures came in at $59.0 million (Q2 2026), $55.7 million (Q1 2026), and $60.8 million (Q4 2025), per Business Quant data.